Neurology
SME
Single asset
Single asset
Neuroplastogen Depression disorders Anhedonia
Elkedonia is developing a neuroplastogen with novel target and mechanism of action able to induce neuroplasticity without psychedelics’ side effects.
This new innovative treatment is for patients suffering from depression, accessible to all, whatever their geographical location, age, or comorbidities, acting rapidly and without risk of dependence, sedation or psychosis, enabling patients to rediscover the pleasures of life, resume their professional activity, and greatly reducing the risk of suicide and relapse
This new innovative treatment is for patients suffering from depression, accessible to all, whatever their geographical location, age, or comorbidities, acting rapidly and without risk of dependence, sedation or psychosis, enabling patients to rediscover the pleasures of life, resume their professional activity, and greatly reducing the risk of suicide and relapse
Yves Ribeill
Partner & EIR
Yves Ribeill founded Scynexis, Inc (NASDAQ: SCYX) and served as its Chairman and CEO from 1999 to 2015. Prior to Scynexis, Inc., Dr. Ribeill served various positions during the 25 years of his international career with Rhone-Poulenc, Aventis. He was involved in discovery and development effort that resulted in the FDA approval of multiple drugs. He has also been a Director of various Biotech companies in Europe and the US.